score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E996K	0.4783	69.0	8e-06	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				PDGFRA p.E996K (Missense)	0.0	MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	MEL-IPI_Pat140-Normal-SM-5VWHZ
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4662	133.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	MEL-IPI_Pat140-Normal-SM-5VWHZ
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat140		
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.E216K	0.4783	23.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC2 p.E216K (Missense)		MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	MEL-IPI_Pat140-Normal-SM-5VWHZ
Biologically Relevant				Somatic Variant	ROS1	Missense	p.C392Y	0.4854	206.0	0.0	0.0																					0				ROS1 p.C392Y (Missense)		MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	MEL-IPI_Pat140-Normal-SM-5VWHZ
Biologically Relevant				Somatic Variant	RB1	Missense	p.H483Y	0.4583	48.0	0.0	0.0																					0				RB1 p.H483Y (Missense)		MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	MEL-IPI_Pat140-Normal-SM-5VWHZ
Biologically Relevant				Somatic Variant	ERG	Missense	p.M385I	0.4878	41.0	0.0	0.0																					0				ERG p.M385I (Missense)		MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	MEL-IPI_Pat140-Normal-SM-5VWHZ
Biologically Relevant				Copy Number	ERRFI1	Deletion				0.0	0.0																					0				ERRFI1 Deletion		MEL-IPI_Pat140	MEL-IPI_Pat140-Tumor-SM-5VWJI	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat140		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.767																									0				COSMIC Signature (version 2) 7 (77%)		MEL-IPI_Pat140		
